GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Celadon Pharmaceuticals PLC (LSE:CEL) » Definitions » YoY EBITDA Growth

Celadon Pharmaceuticals (LSE:CEL) YoY EBITDA Growth : 55.56% (As of Jun. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Celadon Pharmaceuticals YoY EBITDA Growth?

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. Celadon Pharmaceuticals's YoY EBITDA Growth for the quarter that ended in Jun. 2024 was 55.56%.

Celadon Pharmaceuticals's EBITDA per Share for the six months ended in Jun. 2024 was £-0.03.

Celadon Pharmaceuticals YoY EBITDA Growth Historical Data

The historical data trend for Celadon Pharmaceuticals's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Celadon Pharmaceuticals YoY EBITDA Growth Chart

Celadon Pharmaceuticals Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
YoY EBITDA Growth
- - -5,200.00 50.10 56.72

Celadon Pharmaceuticals Semi-Annual Data
Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
YoY EBITDA Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only -876.00 96.14 74.18 -263.64 55.56

Celadon Pharmaceuticals YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

Celadon Pharmaceuticals's YoY EBITDA Growth for the fiscal year that ended in Dec. 2023 is calculated as:

YoY EBITDA Growth (A: Dec. 2023 )
=(EBITDA per Share (A: Dec. 2023 )-EBITDA per Share (A: Dec. 2022 ))/ | EBITDA per Share (A: Dec. 2022 ) |
=(-0.103--0.238)/ | -0.238 |
=56.72 %

Celadon Pharmaceuticals's YoY EBITDA Growth for the quarter that ended in Jun. 2024 is calculated as:

YoY EBITDA Growth (Q: Jun. 2024 )
=(EBITDA per Share (Q: Jun. 2024 )-EBITDA per Share (Q: Jun. 2023 )) / | EBITDA per Share (Q: Jun. 2023 )) |
=(-0.028--0.063)/ | -0.063 |
=55.56 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Celadon Pharmaceuticals YoY EBITDA Growth Related Terms

Thank you for viewing the detailed overview of Celadon Pharmaceuticals's YoY EBITDA Growth provided by GuruFocus.com. Please click on the following links to see related term pages.

Celadon Pharmaceuticals Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Celadon Pharmaceuticals PLC (LSE:CEL) » Definitions » YoY EBITDA Growth
Comparable Companies
LSE:N4P LSE:PXS AQSE:ANA ZTS XTER:MRK NSE:SUNPHARMA TSE:4502 LSE:HLN XSWX:GALD NSE:DIVISLAB HKSE:03692 XSWX:SDZ XTAE:TEVA SHSE:688506 BOM:500087 TSE:4507 SZSE:000538 UTHR NSE:TORNTPHARM BOM:543904
Traded in Other Exchanges
N/A
Address
32-33 Cowcross Street, London, GBR, EC1M 6DF
Website
https://www.celadonpharma.co.uk
Celadon Pharmaceuticals PLC focuses on growing indoor hydroponic high-quality cannabis initially for use within the chronic pain market. It has two reportable segments Celadon is a Build of grow facilities, growing medical grade cannabis and research in the GMP lab, and Harley Street (CPC) is a clinical study into the pain relief benefits of medicinal cannabis. It operates only in the UK and has only one geographical area.

Celadon Pharmaceuticals Headlines

No Headlines